Stock fact sheet · data as of
Indivior Pharmaceuticals Inc (INDV): fair value, margin of safety and Wheel Score
Healthcare · Drug Manufacturers - Specialty & Generic · United States · Value
Is INDV undervalued?
INDV has a margin of safety of 41%: the stock closed at 33.62 on 16 Oct 2026 against a GLS average fair value of 56.88. 2 of the 5 valuation models that produced a number sit above the price. Our screens treat a discount this large as a strong starting point for a cash-secured put, not as a verdict - the fair value is a model output, and a wide gap can mean the models are missing something the market knows.
There is a wide gap between DCF (2.47) and GLS Growth (173.38). When the models are this far apart the "fair value" is really a range, and the margin of safety above should be read with that range in mind.
The nightly engine files INDV under Value: positive earnings at a P/E of 18 or less.
Nine valuation models for INDV
Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.
| Model | Value | vs price | What it measures |
|---|---|---|---|
| DCF | 2.47 | -93% | Present value of the projected free cash flows, discounted at the cost of capital |
| Graham Number | - | - | The most a defensive investor pays for the earnings and book value per share; no value tonight |
| Graham Growth | 58.97 | +75% | Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields |
| Lynch | 18.12 | -46% | EPS × the earnings growth rate (PEG of 1), growth capped at 25% |
| GLS Growth | 173.38 | +416% | EPS compounded ten years at the blended growth rate, discounted back at 15% a year |
| 10 Cap | - | - | Owner's earnings (operating cash flow less maintenance capex) capitalised at 10%; no value tonight |
| Payback Time | - | - | Eight years of compounded free cash flow: the price at which the business pays for itself; no value tonight |
| DDM | - | - | Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend; no value tonight |
| EPV | 31.47 | -6% | Earnings power value: current EPS capitalised at 9% with no growth |
| Zombie (liquidation) | -5.21 | -115% | Current assets less all liabilities, per share: the balance-sheet floor. Not in the average |
| Wall St target | 48.00 | +43% | Analysts' average 12-month price target. Not in the average |
Quality and financial health
Indivior Pharmaceuticals Inc scores only 4 of 9 on the Piotroski F-score, which fails the Sunday Scan's "6 or more" rule. A reading this low means several of the basic tests - positive earnings, positive operating cash flow, falling debt, no new share issuance - are not met. A GLS Moat score of 3.3/10 is a weak reading: the ten-year history the score grades (revenue, EPS, book value, margins, cash flow, share count, ROIC) has not been steady, so the Moat part of the Wheel Score contributes little.
Returns on capital are high - ROIC 83.0%, ROE -214.3%, ROA 17.4% - with debt at -3.58 times equity and negative free cash flow.
Indivior Pharmaceuticals Inc pays no dividend, so the DDM model does not apply and a covered-call holder earns only the premium and any price gain. Revenue comes mainly from Reportable 100% (quarter Q2 FY2026).
Institutional ownership scores 10/10, insider activity 1/10 and Congressional trading 5/10 on the GLS smart-money scales.
| Piotroski F-score | 4 / 9 | ROIC | 83.0% |
|---|---|---|---|
| GLS Moat | 3.3 / 10 | ROE | -214.3% |
| Debt / equity | -3.58 | ROA | 17.4% |
| Free-cash-flow yield | -2.6% | Payout ratio | 0% |
| Institutions | 10 / 10 | Insiders · Congress | 1 · 5 / 10 |
Wheel Score 75: Good
With a Wheel Score of 75 - the Good band - Indivior Pharmaceuticals Inc clears the Sunday Scan's "70 or higher" rule. The parts: Value 25/25, Health 9/20, Moat 5/15, Premium 18/20, Stability 18/20; Moat (5/15) scores lowest.
Implied volatility is 68% on the near-the-money contracts 20-60 days out - above the 60% ceiling of the sweet spot. Premiums are large, but the Wheel Score tapers the Premium points (18 of 20) because volatility this high usually comes with a reason. Chain open interest is 21,158 contracts across all expiries - enough for the wheel at normal size.
Volume runs at 1.7M shares a day on a market cap of $4.2B, with a beta of 1.11; the Stability part of the Wheel Score gives that 18 of 20.
| Part | Points | From | |
|---|---|---|---|
| Value | 25 / 25 | 41% margin of safety | |
| Health | 9 / 20 | Piotroski 4/9 | |
| Moat | 5 / 15 | moat 3.3/10 | |
| Premium | 18 / 20 | implied volatility 68% | |
| Stability | 18 / 20 | 1.7M shares/day, $4.2B cap, beta 1.11 |
The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls; it is updated nightly and is not a recommendation. The walkthrough lesson shows how the score fits into a trade, start to finish.
Upcoming events
Indivior Pharmaceuticals Inc reports earnings on 29 Oct 2026 (before the open) - inside the 14-day window the Sunday Scan avoids, because a put sold now would carry the report's gap risk. The shares go ex-dividend on 30 Oct 2026 (8.13 per share), so a covered call sold before then carries a small early-assignment risk around that date.
Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.
Similar stocks in Drug Manufacturers - Specialty & Generic
The 12 companies below are the closest to Indivior Pharmaceuticals Inc by market cap within the Drug Manufacturers - Specialty & Generic industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.
| Stock | Close | Fair value | MoS | Wheel | Mkt cap |
|---|---|---|---|---|---|
| RGC Regencell Bioscience Holdings Limited | 8.11 | 0.0281 | -28765% | 25Weak | $4.0B |
| AMRX Amneal Pharmaceuticals, Inc. | 19.25 | 12.43 | -55% | 57Fair | $6.1B |
| LNTH Lantheus Holdings, Inc. | 99.99 | 183.99 | +46% | 60Fair | $6.5B |
| ALKS Alkermes plc | 40.10 | 22.14 | -81% | 56Fair | $6.7B |
| HCM HUTCHMED (China) Limited | 13.94 | 2.93 | -376% | 42Weak | $2.4B |
| BHC Bausch Health Companies Inc. | 6.31 | 134.93 | +95% | 45Weak | $2.4B |
| SUPN Supernus Pharmaceuticals, Inc. | 40.18 | 46.46 | +14% | 45Weak | $2.3B |
| PRGO Perrigo Company plc | 15.95 | 37.60 | +58% | 45Weak | $2.2B |
| ALVO Alvotech | 5.31 | - | - | 33No options | $1.9B |
| TRLV Trulieve Cannabis Corp. | 9.97 | 27.65 | +64% | 45Weak | $1.7B |
| ANIP ANI Pharmaceuticals, Inc. | 72.28 | 243.25 | +70% | 77Good | $1.7B |
| RDY Dr. Reddy's Laboratories Limited | 12.75 | 153.50 | +92% | 82Prime | $10.6B |
Screen the whole market the same way
A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the same eight-rule screen, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.
Start free See the Sunday ScanQuestions about INDV
Is INDV undervalued right now?
By the GLS models, yes: at 33.62 the stock is 41% below the average fair value of 56.88 (data as of 16 Oct 2026). Whether the discount is deserved is the question to research next.
What is the Wheel Score of INDV and what does it mean?
INDV scores 75 out of 100 (Good). The Wheel Score blends the margin of safety (25 points), Piotroski health (20), the GLS moat (15), the option premium on offer (20) and trading stability (20) into one number that ranks stocks for the wheel strategy - selling cash-secured puts, then covered calls if assigned. 80 and above is Prime, 65-79 Good, 50-64 Fair, under 50 Weak.
What is the GLS fair value for INDV?
56.88 per share as of 16 Oct 2026 - the simple average of the 5 valuation models (out of nine: DCF, Graham Number, Graham Growth, Lynch, GLS Growth, 10 Cap, Payback Time, DDM and EPV) that produced a positive value. The models run every night on the latest filings; the Quote page lets you switch any of them off and add a margin of safety of your own.
When does Indivior Pharmaceuticals Inc report earnings next?
The next earnings report is due on 29 Oct 2026 (before the open), 13 days from the data date of 16 Oct 2026. The Calendars page lists every upcoming report with its time of day.
Does INDV have listed options, and how liquid are they?
Yes. The nightly snapshot found 334 listed contracts with 21,158 open interest across all expiries and implied volatility of 68% on the near-the-money contracts. The Options scanner lists the cash-secured put and covered call set-ups with premium and annualised yield worked out.